开设账户
模拟账户
关于我们
即时报价及新闻
市场分析
财经日历
每日市场分析
交易平台
下载及介绍
使用教学
交易细则
各项细则
资金提存
推广和资讯
常见问题
联络我们
繁
简
EN
客户登入
开设账户
模拟账户
繁
简
EN
客户登入
开设账户
模拟账户
关于我们
上志国际介绍
上志国际优势
即时报价及新闻
即时报价
即时新闻
市场分析
财经日历
市场分析
交易平台
平台特点
平台教学
交易细则
各项细则
资金提存
推广和资讯
常见问题
联络我们
关于我们
交易细则
贵金属市场
交易平台
市场分析
推广和资讯
常见问题
联络我们
繁
简
EN
Shanghai Gold Exchange Gold T+D rose 1.2% at the morning open to 901.7 yuan/gram on July 10; Silver T+D climbed 3.23% to 14,692.0 yuan/kg.
2026-07-10
Shanghai Gold Exchange Gold T+D rose 1.2% at the morning open to 901.7 yuan/gram on July 10; Silver T+D climbed 3.23% to 14,692.0 yuan/kg.
返回
其他消息
2026-07-10
OpenAI said it will stop development of its AI browser Atlas on Aug. 9 and will fold some Atlas features into the ChatGPT desktop app and a Chrome extension. The decision comes less than a year after OpenAI launched ChatGPT Atlas in Oct. 2025 and abandons its plan to offer a standalone AI browser to challenge Chrome; competitors including Perplexity (Comet) and The Browser Company (Dia) continue pursuing AI browser products.
OpenAI said it will stop development of its AI browser Atlas on Aug. 9 and will fold some Atlas features into the ChatGPT desktop app and a Chrome extension. The decision comes less than a year after OpenAI launched ChatGPT Atlas in Oct. 2025 and abandons its plan to offer a standalone AI browser to challenge Chrome; competitors including Perplexity (Comet) and The Browser Company (Dia) continue pursuing AI browser products.
2026-07-10
July 10 — Novo Nordisk China said the NMPA approved a label update for oral semaglutide tablets (brand: Rybelsus). The drug, approved in China for glycaemic control in adults with type 2 diabetes, had its label revised based on the SOUL trial primary results, which showed a 14% reduction in major adverse cardiovascular events (MACE) in adults with type 2 diabetes and established cardiovascular disease and/or chronic kidney disease.
July 10 — Novo Nordisk China said the NMPA approved a label update for oral semaglutide tablets (brand: Rybelsus). The drug, approved in China for glycaemic control in adults with type 2 diabetes, had its label revised based on the SOUL trial primary results, which showed a 14% reduction in major adverse cardiovascular events (MACE) in adults with type 2 diabetes and established cardiovascular disease and/or chronic kidney disease.
Chat with us
, powered by
LiveChat